Treatment with ISIS 304801 resulted in dose-dependent and prolonged decreases in plasma APOC3 levels when the drug was administered as a single agent ( decreases of 40.032.0 % in the 100-mg group , 63.822.3 % in the 200-mg group , and 79.69.3 % in the 300-mg group , vs. an increase of 4.241.7 % in the placebo group ) and when it was administered as an add-on to fibrates ( decreases of 60.212.5 % in the 200-mg group and 70.913.0 % in the 300-mg group , vs. a decrease of 2.225.2 % in the placebo group ) .